Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only.
Ahmed Zakari
No relevant relationships to disclose
Victor G. Gian
No relevant relationships to disclose
Anthony Alan Meluch
No relevant relationships to disclose
James D. Peyton
No relevant relationships to disclose
David Michael Waterhouse
No relevant relationships to disclose
Andrew J. Lipman
No relevant relationships to disclose
Ralph V. Boccia
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose